Key result
sFASL above ~0.1 ng/ml is linked to worse chronic heart failure progression and mortality.
Why the study?
To present the structure and mechanism of FAS family action, the clinical purpose of measuring biomarker concentrations in serum, their relationship with HF functional class, and the use of sFASL to predict HF course.
Does the concentration of FAS system biomarkers predict the clinical course and severity in patients with chronic heart failure?
Does the concentration of FAS system biomarkers predict the clinical course and severity in patients with chronic heart failure?
Elevated serum sFASL levels (≥0.0999 ng/ml) may serve as a prognostic biomarker for disease severity, progression, and mortality in patients with chronic heart failure.
The authors conducted the descriptive literature synthesis to present the structure and mechanism of the FAS family action, the purpose of determining the concentration of biomarkers in blood serum, the relationship of various FAS ligands levels with the patient’s clinical condition - the HF functional class (FC), as well as the sFASL using possibility to predict the HF course. The review analyzed 22 studies on the FAS system biomarkers participation in the HF pathogenesis and the relationship of their serum concentrations with the HF severity. A threshold sFASL value of 0.0999 ng/ml is associated with this pathology unfavorable course, while the increase in sFASL degree directly correlates with an increase in the FC of HF, the progression and death risks.
No takes yet. Share an insight, caveat, or question.
Tokmachev et al. (2024) conducted a review in chronic heart failure. FAS system biomarkers (sFASL) was evaluated on HF severity, progression, and death risks. A threshold sFASL value of 0.0999 ng/ml is associated with an unfavorable course of chronic heart failure, directly correlating with increased functional class, progression, and death risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: